CN1195519C - 5－HT再摄取抑制剂与h5－HT1B拮抗剂或部分激动剂的组合物 - Google Patents

5－HT再摄取抑制剂与h5－HT1B拮抗剂或部分激动剂的组合物 Download PDF

Info

Publication number
CN1195519C
CN1195519C CNB98811206XA CN98811206A CN1195519C CN 1195519 C CN1195519 C CN 1195519C CN B98811206X A CNB98811206X A CN B98811206XA CN 98811206 A CN98811206 A CN 98811206A CN 1195519 C CN1195519 C CN 1195519C
Authority
CN
China
Prior art keywords
component
naphthyl
compositions
methyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB98811206XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1278729A (zh
Inventor
S·贝里
S·罗斯
S·－O·托尔贝里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1278729A publication Critical patent/CN1278729A/zh
Application granted granted Critical
Publication of CN1195519C publication Critical patent/CN1195519C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Replacement Of Web Rolls (AREA)
  • Winding, Rewinding, Material Storage Devices (AREA)
CNB98811206XA 1997-09-18 1998-09-09 5－HT再摄取抑制剂与h5－HT1B拮抗剂或部分激动剂的组合物 Expired - Fee Related CN1195519C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE97033757 1997-09-18
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination

Publications (2)

Publication Number Publication Date
CN1278729A CN1278729A (zh) 2001-01-03
CN1195519C true CN1195519C (zh) 2005-04-06

Family

ID=20408295

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB98811206XA Expired - Fee Related CN1195519C (zh) 1997-09-18 1998-09-09 5－HT再摄取抑制剂与h5－HT1B拮抗剂或部分激动剂的组合物

Country Status (29)

Country Link
US (1) US6159971A (enExample)
EP (1) EP1014985B1 (enExample)
JP (1) JP2001516718A (enExample)
KR (1) KR20010024076A (enExample)
CN (1) CN1195519C (enExample)
AR (1) AR015448A1 (enExample)
AT (1) ATE240733T1 (enExample)
AU (1) AU752722B2 (enExample)
BR (1) BR9812088A (enExample)
CA (1) CA2302382A1 (enExample)
DE (1) DE69814882T2 (enExample)
DK (1) DK1014985T3 (enExample)
EE (1) EE04141B1 (enExample)
ES (1) ES2200370T3 (enExample)
HU (1) HUP0200602A3 (enExample)
IL (1) IL134776A0 (enExample)
IS (1) IS5406A (enExample)
MY (1) MY116280A (enExample)
NO (1) NO20001399L (enExample)
NZ (1) NZ503171A (enExample)
PL (1) PL339371A1 (enExample)
PT (1) PT1014985E (enExample)
RU (1) RU2214824C2 (enExample)
SE (1) SE9703375D0 (enExample)
SK (1) SK2852000A3 (enExample)
TR (1) TR200000727T2 (enExample)
TW (1) TW589183B (enExample)
WO (1) WO1999013877A1 (enExample)
ZA (1) ZA987817B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
MXPA03008777A (es) * 2001-05-01 2004-02-12 Lundbeck & Co As H El uso de escitalopram enantiomericamente puro.
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR100511288B1 (ko) * 2003-11-14 2005-08-31 엘지전자 주식회사 4대의 압축기를 구비한 공기조화기의 실외기
US20060217394A1 (en) * 2005-02-23 2006-09-28 Silvan S. Tomkins Institute, Inc. Treatment of anhedonia
EP1912650B8 (en) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CN104721168A (zh) 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放系统及其制造方法
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DK0533268T3 (da) * 1991-09-18 2001-12-03 Glaxo Group Ltd Benzanilidderivater som 5HT-1D antagonister
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination

Also Published As

Publication number Publication date
ES2200370T3 (es) 2004-03-01
EE04141B1 (et) 2003-10-15
KR20010024076A (ko) 2001-03-26
NO20001399D0 (no) 2000-03-17
ATE240733T1 (de) 2003-06-15
WO1999013877A1 (en) 1999-03-25
NO20001399L (no) 2000-05-10
DK1014985T3 (da) 2003-09-15
NZ503171A (en) 2002-02-01
BR9812088A (pt) 2000-09-26
CA2302382A1 (en) 1999-03-25
AU9193098A (en) 1999-04-05
IS5406A (is) 2000-03-15
SE9703375D0 (sv) 1997-09-18
HUP0200602A3 (en) 2003-04-28
EP1014985B1 (en) 2003-05-21
IL134776A0 (en) 2001-04-30
SK2852000A3 (en) 2000-09-12
PL339371A1 (en) 2000-12-18
PT1014985E (pt) 2003-10-31
EE200000141A (et) 2001-02-15
TR200000727T2 (tr) 2000-09-21
AR015448A1 (es) 2001-05-02
MY116280A (en) 2003-12-31
TW589183B (en) 2004-06-01
DE69814882D1 (de) 2003-06-26
HUP0200602A2 (hu) 2002-07-29
HK1032739A1 (en) 2001-08-03
AU752722B2 (en) 2002-09-26
CN1278729A (zh) 2001-01-03
RU2214824C2 (ru) 2003-10-27
US6159971A (en) 2000-12-12
EP1014985A1 (en) 2000-07-05
JP2001516718A (ja) 2001-10-02
ZA987817B (en) 1999-03-18
DE69814882T2 (de) 2004-05-19

Similar Documents

Publication Publication Date Title
CN1195519C (zh) 5－HT再摄取抑制剂与h5－HT1B拮抗剂或部分激动剂的组合物
CN1270585A (zh) 取代的1,2,3,4－四氢化萘衍生物
CN1150166C (zh) Cb2受体拮抗剂化合物
CN1156451C (zh) β2-肾上腺受体激动剂
CN1274676C (zh) 喹啉和喹唑啉衍生物
CN1231468C (zh) 化合物
CN1245376C (zh) 取代的2－二烷基氨基烷基联苯衍生物
CN1656075A (zh) 喹啉衍生物和其作为5－ht6配体的用途
CN100340562C (zh) 杂环稠合的苯并二噁烷的抗抑郁芳基哌嗪衍生物
CN1930138A (zh) 取代的吗啉和硫代吗啉衍生物
CN1133593A (zh) 用于治疗的哌嗪化合物
CN1527816A (zh) 新的具有5-ht6受体亲和性的吲哚衍生物
CN101056845A (zh) 取代的苯胺衍生物
CN1906180A (zh) 新的长效β－2－激动剂及其作为药物的用途
CN1094037A (zh) N-苯甲酰苯胺衍生物
CN88102018A (zh) 1-苯基-3-萘氧基丙胺
CN1278727A (zh) 单胺氧化酶抑制剂和h5－ht1B拮抗剂或部分激动剂的组合
CN1230432C (zh) 取代的苯基－哌嗪衍生物及其制备和用途
CN1646528A (zh) 作为有效的α2－肾上腺素受体拮抗剂的多环化合物
CN1419534A (zh) 治疗用的二苯基醚化合物
CN1244577C (zh) 4－苯基－1－哌嗪基、－哌啶基和－四氢吡啶基衍生物
CN1246110A (zh) 芳基哌啶子基丙醇和芳基哌嗪子基丙醇衍生物和含有它们的药物
CN1145606C (zh) 2-氨基1,2,3,4-四氢化萘、其制备方法及其预防和治疗炎症和/或自身免疫性疾病的药物组合物
CN1139584C (zh) 杂环化合物、其制备方法以及含有该化合物的药物组合物
CN1309722C (zh) 抗抑郁的杂环稠合的苯并二噁烷的环烷基胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee